Company profile: Eurogentec
1.1 - Company Overview
Company description
- Provider of GMP biopharmaceutical manufacturing and life science solutions for research, diagnostic and pharmaceutical markets, including large-scale production of plasmid DNA, recombinant proteins, antibody fragments, mRNA, vaccines and conjugates; complex and NGS oligonucleotides; peptide-oligo conjugates; custom RNA/DNA aptamers; reagents and kits, in compliance with local and international standards.
Products and services
- Large scale mRNA production: Produces mRNA in GMP facilities, optimized to synthesize and purify up to 50 grams of material per batch, delivering GMP-grade material
- Large scale GMP Biopharmaceutical Manufacturing: Engineers plasmid DNA, recombinant proteins, and antibody fragments up to kilogram scale for clinical and commercial human uses, via GMP-compliant manufacturing
- Complex Oligonucleotides: Fabricates complex oligonucleotides featuring atypical chemistries, rare modifications, and personalized labels and packages, delivered as custom-engineered products
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Eurogentec
WuXi Advanced Therapies
HQ: United States
Website
- Description: Provider of CDMO and integrated laboratory testing services to accelerate bio-based drugs, including TESSA scalable AAV vector production; XOFLX packaging and producer cell lines for lentiviral vectors; process development, IND-enabling studies, and phase-appropriate clinical manufacturing; plus comprehensive testing (viral clearance, biosafety, release, cell banking, stability) for cell and gene therapies, monoclonal antibodies, and vaccines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full WuXi Advanced Therapies company profile →
Oruka Therapeutics
HQ: United States
Website
- Description: Provider of biologic therapies for chronic skin diseases, including monoclonal antibodies: ORKA-001 targeting IL-23p19 for psoriasis and other inflammatory diseases; ORKA-002 targeting IL-17A/F for psoriasis and other inflammatory diseases; and ORKA-003, a discovery-stage program for psoriasis, psoriatic arthritis, and related conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oruka Therapeutics company profile →
CBPartners
HQ: United States
Website
- Description: Provider of strategy consulting services focused on strategic issues for multinational pharmaceutical, biopharmaceutical, and medical device companies, as well as governments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CBPartners company profile →
OcellO
HQ: The Netherlands
Website
- Description: Provider of CRO services for the drug discovery industry, developing clinically relevant in vitro human micro-tissue models for screening and profiling of small molecules and biologics to improve the efficiency of lead development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OcellO company profile →
Aiolos Bio
HQ: United States
Website
- Description: Provider of therapies for respiratory and immune conditions, initially advancing AIO-001, a monoclonal antibody for moderate-to-severe asthma dosed every 6 months. Offers vaccines for meningitis, shingles, RSV, flu, and polio; specialty and general medicines for HIV, asthma, COPD, lupus, cancer, and skin diseases; conducts infectious disease research and develops respiratory/immunology solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aiolos Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Eurogentec
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Eurogentec
2.2 - Growth funds investing in similar companies to Eurogentec
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Eurogentec
4.2 - Public trading comparable groups for Eurogentec
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →